2023-508543-42-00CompletedPhase 1
A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 4-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure (CHF)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Mar 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (actual)
- First submitted
- 20 Nov 2023
- Start date
- 22 Jan 2024
- Lead sponsor
- Corteria Pharmaceuticals
- Diseases
- Heart failure
- EU CT number
- 2023-508543-42-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 94
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Deventer Ziekenhuis | Deventer | Netherlands | Completed |
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
| D & A Research B.V. | Sneek | Netherlands | Completed |
| Stichting Viecuri Medisch Centrum voor Noord-Limburg | Venlo | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.